Bioventus Q3 Revenue Grows 3%; Cash Flow Healthy
Bioventus reported Q3 revenue of $142.4 million, driven by Pain Treatments, and Non-GAAP earnings of $0.17 per share. The company continues to review strategic alternatives.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed